Related Experiment Video
Updated: Dec 27, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and
Snehal Palwe1, Balaji Veeraraghavan2, Hariharan Periasamy3
1SB College of Science, Aurangabad, India.
Abstract:
In India and China, indigenous drug manufacturers market arbitrarily combined parenteral β-lactam and β-lactamase inhibitors (BL-BLIs). In these fixed-dose combinations, sulbactam or tazobactam is indiscriminately combined with parenteral cephalosporins, with BLI doses kept in ratios similar to those for the approved BL-BLIs. Such combinations have been introduced into clinical practice without mandatory drug development studies involving pharmacokinetic/pharmacodynamic, safety, and efficacy assessments being undertaken. Such unorthodox combinations compromise clinical outcomes and also potentially contribute to resistance development.
More Related Videos
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Acute Pyelonephritis II: Diagnostic Studies and Management
Development of Antibiotic Resistance
Antibiotic Selection
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care